patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_426652 | REC_0016001 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 7.4 | 76 | female | 2 | 17 | 3.7 | 3 | sotorasib 960 mg daily | 11.6 | true | MSS | 2026-03-15T05:36:01.554513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386994 | REC_0016002 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.7 | 77 | female | 2 | 74 | 6.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.7 | false | MSS | 2026-03-15T05:36:01.555179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442608 | REC_0016003 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.5 | 62 | male | 1 | 35 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.2 | false | MSS | 2026-03-15T05:36:01.555831+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_620071 | REC_0016004 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 7.4 | 70 | female | 2 | 9 | 6.7 | 2 | entrectinib 600 mg daily | 18 | true | MSS | 2026-03-15T05:36:01.556578+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267402 | REC_0016005 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11.9 | 71 | female | 2 | 22 | 4.2 | 5 | osimertinib 80 mg daily | 7.8 | false | MSS | 2026-03-15T05:36:01.556988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948539 | REC_0016006 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.7 | 75 | female | 2 | 7 | 4.5 | 5 | pembrolizumab 200 mg q3w | 8.8 | true | MSS | 2026-03-15T05:36:01.558331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_145084 | REC_0016007 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 9.3 | 66 | female | 1 | 11 | 4.9 | 1 | osimertinib 80 mg daily | 20 | true | MSS | 2026-03-15T05:36:01.558780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247109 | REC_0016008 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 11 | 78 | male | 0 | 15 | 5 | 1 | sotorasib 960 mg daily | 21.4 | false | MSI-H | 2026-03-15T05:36:01.559173+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826736 | REC_0016009 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 10.2 | 76 | male | 1 | 14 | 6.4 | 6 | entrectinib 600 mg daily | 6.9 | false | MSS | 2026-03-15T05:36:01.559527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641322 | REC_0016010 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 9.8 | 59 | male | 0 | 2 | 4.3 | 3 | osimertinib 80 mg daily | 10.7 | true | MSS | 2026-03-15T05:36:01.559863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844254 | REC_0016011 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 20.6 | 75 | female | 1 | 17 | 4.5 | 6 | alectinib 600 mg BID | 16.8 | false | MSI-H | 2026-03-15T05:36:01.560280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584608 | REC_0016012 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 3.3 | 70 | female | 1 | 15 | 7.1 | 7 | sotorasib 960 mg daily | 12.5 | false | MSS | 2026-03-15T05:36:01.560695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535936 | REC_0016013 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.1 | 79 | male | 1 | 48 | 7 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.7 | true | MSS | 2026-03-15T05:36:01.561088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489438 | REC_0016014 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 6.3 | 70 | female | 2 | 47 | 5.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 15.6 | true | MSS | 2026-03-15T05:36:01.561491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923451 | REC_0016015 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10 | 58 | male | 1 | 9 | 7 | 5 | alectinib 600 mg BID | 13.7 | true | MSS | 2026-03-15T05:36:01.561900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560829 | REC_0016016 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 12.9 | 67 | female | 0 | 10 | 6.1 | 6 | alectinib 600 mg BID | 9.9 | true | MSS | 2026-03-15T05:36:01.562272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794401 | REC_0016017 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 20 | 8 | 66 | female | 1 | 15 | 5.3 | 0 | osimertinib 80 mg daily | 32.2 | false | MSS | 2026-03-15T05:36:01.562858+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_555552 | REC_0016018 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 3.9 | 68 | female | 0 | 23 | 5.7 | 5 | osimertinib 80 mg daily | 4.8 | false | MSS | 2026-03-15T05:36:01.563320+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989201 | REC_0016019 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12.4 | 74 | male | 2 | 14 | 6 | 6 | sotorasib 960 mg daily | 4.7 | false | MSI-H | 2026-03-15T05:36:01.563752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_604129 | REC_0016020 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 22 | 3.8 | 76 | female | 1 | 58 | 7.2 | 0 | carboplatin + paclitaxel + pembrolizumab | 51.1 | true | MSS | 2026-03-15T05:36:01.564187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_426632 | REC_0016021 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 11 | 54 | female | 0 | 15 | 6.1 | 1 | osimertinib 80 mg daily | 21.4 | false | MSI-H | 2026-03-15T05:36:01.564637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874641 | REC_0016022 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 8.7 | 70 | female | 1 | 22 | 5.2 | 2 | sotorasib 960 mg daily | 24 | false | MSS | 2026-03-15T05:36:01.565275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736720 | REC_0016023 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 9.4 | 73 | female | 2 | 14 | 7.3 | 6 | alectinib 600 mg BID | 12.8 | false | MSS | 2026-03-15T05:36:01.565760+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144849 | REC_0016024 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11.4 | 62 | female | 0 | 15 | 6.7 | 2 | entrectinib 600 mg daily | 6.3 | false | MSS | 2026-03-15T05:36:01.566161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141707 | REC_0016025 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 8.2 | 73 | female | 1 | 13 | 5.2 | 7 | osimertinib 80 mg daily | 10.2 | false | MSS | 2026-03-15T05:36:01.566517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850856 | REC_0016026 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 6.2 | 64 | male | 0 | 15 | 4.1 | 2 | osimertinib 80 mg daily | 13.3 | true | MSS | 2026-03-15T05:36:01.566910+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_921154 | REC_0016027 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 16.4 | 54 | female | 0 | 11 | 4.2 | 6 | sotorasib 960 mg daily | 13.6 | false | MSS | 2026-03-15T05:36:01.567286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702165 | REC_0016028 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 15.3 | 74 | female | 1 | 7 | 5.9 | 9 | osimertinib 80 mg daily | 7.7 | true | MSI-H | 2026-03-15T05:36:01.567658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241993 | REC_0016029 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 32 | 11.2 | 76 | female | 0 | 10 | 4.3 | 1 | pembrolizumab 200 mg q3w | 22.1 | false | MSI-H | 2026-03-15T05:36:01.568454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_156608 | REC_0016030 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 31 | 5.6 | 74 | male | 2 | 47 | 7.7 | 1 | pembrolizumab 200 mg q3w | 13.4 | true | MSS | 2026-03-15T05:36:01.569105+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_661890 | REC_0016031 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 13.9 | 66 | female | 1 | 0 | 5.1 | 5 | sotorasib 960 mg daily | 9.6 | false | MSS | 2026-03-15T05:36:01.569580+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_126124 | REC_0016032 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 15.3 | 67 | female | 1 | 18 | 4.9 | 4 | osimertinib 80 mg daily | 10.9 | true | MSI-H | 2026-03-15T05:36:01.570019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757798 | REC_0016033 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 9.3 | 68 | male | 0 | 16 | 7 | 6 | sotorasib 960 mg daily | 12.7 | true | MSS | 2026-03-15T05:36:01.570446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_163013 | REC_0016034 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 6.1 | 69 | female | 1 | 4 | 5 | 6 | pembrolizumab 200 mg q3w | 6.8 | false | MSS | 2026-03-15T05:36:01.570839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813310 | REC_0016035 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 36 | 4.4 | 67 | male | 1 | 62 | 5.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.3 | false | MSS | 2026-03-15T05:36:01.571230+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877062 | REC_0016036 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 12.6 | 65 | male | 1 | 17 | 6.3 | 4 | entrectinib 600 mg daily | 11.3 | false | MSS | 2026-03-15T05:36:01.571618+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864750 | REC_0016037 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 33 | 7.9 | 73 | female | 1 | 17 | 4.2 | 1 | entrectinib 600 mg daily | 23.3 | true | MSS | 2026-03-15T05:36:01.572026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521496 | REC_0016038 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 14.7 | 55 | male | 1 | 12 | 5 | 7 | osimertinib 80 mg daily | 17.9 | false | MSI-H | 2026-03-15T05:36:01.574262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213077 | REC_0016039 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 8.8 | 76 | female | 1 | 15 | 4.2 | 6 | alectinib 600 mg BID | 12.4 | false | MSS | 2026-03-15T05:36:01.574759+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_206309 | REC_0016040 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 28 | 7.8 | 70 | female | 3 | 12 | 4.6 | 0 | entrectinib 600 mg daily | 42.8 | false | MSS | 2026-03-15T05:36:01.575130+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939346 | REC_0016041 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12.4 | 80 | female | 1 | 12 | 7.7 | 5 | osimertinib 80 mg daily | 13.6 | false | MSI-H | 2026-03-15T05:36:01.575524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400632 | REC_0016042 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.3 | 81 | female | 1 | 7 | 6 | 5 | alectinib 600 mg BID | 7.8 | false | MSS | 2026-03-15T05:36:01.575918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158732 | REC_0016043 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 6.4 | 63 | female | 0 | 13 | 5.7 | 1 | pembrolizumab 200 mg q3w | 16.3 | true | MSS | 2026-03-15T05:36:01.576571+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356971 | REC_0016044 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 12.1 | 68 | female | 1 | 11 | 5 | 2 | sotorasib 960 mg daily | 21.4 | false | MSS | 2026-03-15T05:36:01.577040+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970731 | REC_0016045 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 7.8 | 71 | male | 1 | 17 | 7.8 | 1 | sotorasib 960 mg daily | 13.8 | false | MSS | 2026-03-15T05:36:01.577461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_586673 | REC_0016046 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 15.6 | 64 | female | 1 | 12 | 7.3 | 5 | osimertinib 80 mg daily | 9.4 | false | MSI-H | 2026-03-15T05:36:01.577844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366844 | REC_0016047 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 7.7 | 76 | female | 2 | 46 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.4 | false | MSS | 2026-03-15T05:36:01.578229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577938 | REC_0016048 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 15.2 | 83 | female | 1 | 13 | 6.2 | 2 | osimertinib 80 mg daily | 19.1 | false | MSI-H | 2026-03-15T05:36:01.578618+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786476 | REC_0016049 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 13 | 11 | 61 | male | 1 | 15 | 6.2 | 6 | entrectinib 600 mg daily | 12.5 | false | MSS | 2026-03-15T05:36:01.578993+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_632275 | REC_0016050 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 17.5 | 59 | female | 0 | 11 | 7.4 | 2 | sotorasib 960 mg daily | 24.8 | true | MSI-H | 2026-03-15T05:36:01.579340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451472 | REC_0016051 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 8 | 61 | female | 0 | 14 | 8.6 | 6 | osimertinib 80 mg daily | 9.8 | true | MSS | 2026-03-15T05:36:01.579684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_432068 | REC_0016052 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 10.9 | 51 | female | 0 | 17 | 7 | 4 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:36:01.580127+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504350 | REC_0016053 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 12.4 | 73 | male | 2 | 10 | 5.1 | 2 | osimertinib 80 mg daily | 26.2 | true | MSS | 2026-03-15T05:36:01.580536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233738 | REC_0016054 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 34 | 15.3 | 60 | male | 0 | 19 | 6.4 | 2 | entrectinib 600 mg daily | 23.7 | true | MSI-H | 2026-03-15T05:36:01.580907+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867144 | REC_0016055 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 4.6 | 74 | female | 1 | 7 | 6.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:36:01.581275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774310 | REC_0016056 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 10.1 | 72 | male | 1 | 7 | 4.2 | 1 | entrectinib 600 mg daily | 7.6 | false | MSS | 2026-03-15T05:36:01.582024+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213951 | REC_0016057 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 9.8 | 62 | female | 1 | 58 | 5.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 7.6 | true | MSS | 2026-03-15T05:36:01.582550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482708 | REC_0016058 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 4.5 | 71 | female | 2 | 54 | 6.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 24.2 | false | MSS | 2026-03-15T05:36:01.583000+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623366 | REC_0016059 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 5 | 77 | female | 2 | 9 | 6.5 | 2 | pembrolizumab 200 mg q3w | 18.1 | false | MSS | 2026-03-15T05:36:01.583566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281719 | REC_0016060 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 11.5 | 69 | female | 1 | 17 | 7 | 6 | osimertinib 80 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:36:01.584144+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660349 | REC_0016061 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 7.1 | 65 | male | 1 | 11 | 5.8 | 1 | osimertinib 80 mg daily | 17.8 | false | MSS | 2026-03-15T05:36:01.584644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_335627 | REC_0016062 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 15.6 | 76 | female | 1 | 19 | 5.7 | 1 | osimertinib 80 mg daily | 19.9 | true | MSS | 2026-03-15T05:36:01.585074+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927093 | REC_0016063 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 8.9 | 63 | male | 0 | 15 | 6.1 | 3 | osimertinib 80 mg daily | 9.1 | false | MSS | 2026-03-15T05:36:01.585471+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707301 | REC_0016064 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 12 | 73 | female | 2 | 13 | 6.4 | 2 | osimertinib 80 mg daily | 15 | false | MSI-H | 2026-03-15T05:36:01.585866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181321 | REC_0016065 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 13.5 | 60 | male | 1 | 16 | 3.4 | 1 | alectinib 600 mg BID | 20.6 | false | MSI-H | 2026-03-15T05:36:01.586286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596440 | REC_0016066 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6 | 58 | male | 1 | 73 | 2.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 14.2 | false | MSS | 2026-03-15T05:36:01.586682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868372 | REC_0016067 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 33 | 5 | 70 | male | 1 | 16 | 4.3 | 1 | sotorasib 960 mg daily | 12.5 | true | MSS | 2026-03-15T05:36:01.587111+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871863 | REC_0016068 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 12 | 58 | female | 1 | 20 | 4.9 | 1 | sotorasib 960 mg daily | 15.5 | true | MSS | 2026-03-15T05:36:01.587518+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928819 | REC_0016069 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 13.8 | 55 | male | 0 | 18 | 8.4 | 1 | sotorasib 960 mg daily | 27.2 | false | MSS | 2026-03-15T05:36:01.588184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811379 | REC_0016070 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12.4 | 63 | female | 0 | 10 | 3.9 | 7 | osimertinib 80 mg daily | 6.1 | false | MSS | 2026-03-15T05:36:01.588637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862023 | REC_0016071 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 8.4 | 66 | female | 0 | 59 | 5.8 | 4 | pembrolizumab 200 mg q3w | 14.3 | true | MSS | 2026-03-15T05:36:01.589016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473509 | REC_0016072 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 16.7 | 80 | male | 3 | 21 | 3.6 | 2 | osimertinib 80 mg daily | 18.9 | true | MSS | 2026-03-15T05:36:01.589418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868096 | REC_0016073 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 15.1 | 76 | female | 1 | 10 | 5 | 6 | pembrolizumab 200 mg q3w | 4 | true | MSI-H | 2026-03-15T05:36:01.589802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187874 | REC_0016074 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 32 | 6.9 | 67 | female | 0 | 18 | 5.5 | 0 | alectinib 600 mg BID | 48.1 | false | MSS | 2026-03-15T05:36:01.590179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_695115 | REC_0016075 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 14.4 | 66 | female | 0 | 6 | 5.9 | 2 | osimertinib 80 mg daily | 23 | false | MSI-H | 2026-03-15T05:36:01.590575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543301 | REC_0016076 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 28 | 9.9 | 53 | male | 0 | 2 | 6.5 | 0 | entrectinib 600 mg daily | 25.9 | true | MSS | 2026-03-15T05:36:01.590977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681767 | REC_0016077 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 16.8 | 75 | male | 1 | 16 | 6.2 | 2 | osimertinib 80 mg daily | 19.1 | false | MSI-H | 2026-03-15T05:36:01.591368+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617447 | REC_0016078 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.6 | 62 | male | 1 | 15 | 4.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.1 | true | MSS | 2026-03-15T05:36:01.591757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268231 | REC_0016079 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 10.6 | 74 | female | 2 | 13 | 5.8 | 6 | osimertinib 80 mg daily | 13.2 | true | MSI-H | 2026-03-15T05:36:01.592233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680056 | REC_0016080 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 23 | 5.5 | 46 | male | 0 | 102 | 6.3 | 0 | carboplatin + paclitaxel + pembrolizumab | 26.2 | false | MSS | 2026-03-15T05:36:01.592796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_492892 | REC_0016081 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 12.1 | 56 | female | 0 | 11 | 5 | 6 | entrectinib 600 mg daily | 6.7 | true | MSI-H | 2026-03-15T05:36:01.593243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289254 | REC_0016082 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 9.9 | 63 | female | 0 | 20 | 7.3 | 6 | entrectinib 600 mg daily | 16.6 | false | MSS | 2026-03-15T05:36:01.593845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633916 | REC_0016083 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 30 | 8.1 | 71 | female | 1 | 6 | 4.4 | 2 | pembrolizumab 200 mg q3w | 8.8 | true | MSS | 2026-03-15T05:36:01.594300+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962581 | REC_0016084 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 13.3 | 71 | female | 2 | 26 | 3.5 | 2 | osimertinib 80 mg daily | 20.2 | false | MSS | 2026-03-15T05:36:01.594726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217877 | REC_0016085 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 30 | 5.3 | 73 | female | 2 | 34 | 5.7 | 0 | carboplatin + paclitaxel + pembrolizumab | 39 | true | MSS | 2026-03-15T05:36:01.595129+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488991 | REC_0016086 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 18 | 6.5 | 68 | male | 1 | 21 | 6.9 | 7 | pembrolizumab 200 mg q3w | 8.6 | true | MSS | 2026-03-15T05:36:01.595542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_630158 | REC_0016087 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 6.5 | 64 | male | 0 | 14 | 6 | 4 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:36:01.595946+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_446211 | REC_0016088 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 18 | 1.5 | 70 | female | 2 | 18 | 4.8 | 6 | pembrolizumab 200 mg q3w | 11 | false | MSS | 2026-03-15T05:36:01.596422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652200 | REC_0016089 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 13.7 | 67 | female | 0 | 8 | 7.8 | 1 | entrectinib 600 mg daily | 18.4 | false | MSS | 2026-03-15T05:36:01.596864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797917 | REC_0016090 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 12.1 | 76 | female | 2 | 20 | 2.6 | 2 | osimertinib 80 mg daily | 13.9 | false | MSI-H | 2026-03-15T05:36:01.597244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729403 | REC_0016091 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 12.8 | 57 | male | 0 | 19 | 6 | 2 | osimertinib 80 mg daily | 11.8 | false | MSI-H | 2026-03-15T05:36:01.597623+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914918 | REC_0016092 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 4.1 | 68 | female | 0 | 24 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 13 | false | MSS | 2026-03-15T05:36:01.598059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412091 | REC_0016093 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 4.1 | 72 | female | 1 | 78 | 6.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.8 | true | MSS | 2026-03-15T05:36:01.598742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558419 | REC_0016094 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 4.1 | 63 | male | 0 | 34 | 6.6 | 2 | pembrolizumab 200 mg q3w | 11.3 | false | MSS | 2026-03-15T05:36:01.599151+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667473 | REC_0016095 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 12.5 | 65 | male | 1 | 10 | 7.7 | 4 | osimertinib 80 mg daily | 7.6 | false | MSI-H | 2026-03-15T05:36:01.599747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_674266 | REC_0016096 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 10 | 74 | female | 2 | 15 | 5.9 | 1 | alectinib 600 mg BID | 14.8 | false | MSI-H | 2026-03-15T05:36:01.600275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817397 | REC_0016097 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 9.4 | 76 | female | 2 | 16 | 5.9 | 1 | osimertinib 80 mg daily | 22.8 | false | MSS | 2026-03-15T05:36:01.600683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704063 | REC_0016098 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 5.3 | 70 | female | 1 | 10 | 5.8 | 1 | entrectinib 600 mg daily | 20.3 | false | MSS | 2026-03-15T05:36:01.601091+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119264 | REC_0016099 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 11 | 59 | female | 1 | 3 | 5.9 | 1 | alectinib 600 mg BID | 23.9 | false | MSI-H | 2026-03-15T05:36:01.601514+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944464 | REC_0016100 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 18.4 | 76 | male | 1 | 25 | 5.8 | 5 | entrectinib 600 mg daily | 15.8 | false | MSS | 2026-03-15T05:36:01.601913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.